Alogliptin in the treatment of type 2 diabetes mellitus: an evidence base for the clinical use


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Type 2 diabetes is a serious disease associated with the development of severe complications. The current treatment, including the use of drugs based on the “incretin effects", and the mechanism of action of dipeptidyl peptidase-4 inhibitors are discussed. The results of clinical studies of the efficacy and safety of alogliptin are presented.

全文:

受限制的访问

作者简介

E. Biryukova

A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Email: lena@obsudim.ru
MD, Professor, Department of Endocrinology and Diabetology

参考

  1. Papatheodorou K., Papanas N., Banach M., et ai. Complications of Diabetes. J. Diab. Res. 2016;2016:6989453.
  2. Vilsboll T., Holst J.J. incretins, insulin secretion and type 2 diabetes mellitus. Diabetol. 2004; 47:357-66.
  3. Pratley R.E., Salsali A. inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr. Med. Res. Opin. 2007;23:919-31.
  4. Aroda V.R., Henry R.R., Han J., et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: Meta-analysis and systematic review. Clin. Ther. 2012;34(6):1247-58.
  5. Deacon C.F. Dipeptidylpeptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diab. Obes. Metab. 2011;13: 7-18.
  6. Deacon C.F, Lebovitz H.E. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diab. Obes. Metab. 2016;18:333-47.
  7. Johns E., McKay G., Fisher M. Dipeptidyl peptidase-4 (DPP-4) inhibitors. Br. J. Cardiol. 2017;24:(1). doi: 10.5837/bjc.2017.001.
  8. Lim S.W, Jin J. Z., Jin L., et al. Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation. Kor. J. intern. Med. 2015;30(6):759-70.
  9. Godinho R., Mega C., Teixeira-de-Lemos E., et al. The Place of Dipeptidyl Peptidase-4 inhibitors in Type 2 Diabetes Therapeutics: A «Me Too» or «the Special One» Antidiabetic Class? J. Diab. Res. 2015;2015:1-28. doi: 10.1155/2015/806979.
  10. Gooßen K, G.räber S. Longer term safety of dipeptidyl peptidase-4 in- hibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diab. Obes. Metab. 2012;14:1061-72.
  11. Алгоритмы специализированной медицинской помощи больных сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, 8-й выпуск. М., 2017. [Algorithms of specialized medical care for patients with diabetes mellitus: clinical guidelines. Ed. by i.i. Dedov, M.V. Shestakova. Moscow, 2017. (in Russ.)].
  12. Baetta R., Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors. Drugs 2011;71(11):1441-67.
  13. Saisho Y. Alogliptin benzoate for management of type 2 diabetes. Vasc. Health Risk Management. 2015:11:229-43.
  14. Dineen L., Law C., Scher R. Alogliptin (Nesina) for Adults With Type-2 Diabetes. PT. 2014;39(3):186, 192-8, 202.
  15. Seino Y., Fujita T., Hiroi S., et al. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study Curr. Med. Res. Opin. 2011;27:1781-92.
  16. DeFronzo R.A., Fleck P.R., Wilson C.A., Mekki Q. Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, doubleblind, place-bo-controlled study. Diab. Care. 2008;31:2315-17.
  17. Capuano A Sportiello L., Maiorino M.I., Rossi F, et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy - focus on alogliptin. Drug Des. Devel. Ther. 2013;7:989-1001.
  18. Seino Y., Yabe D. Alogliptin benzoate for the treatment of type 2 diabetes. Exp. Opin. Pharmacother. 2014;15(6):851-63.
  19. Liu Y., Hong T. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diab. Obes. Metab. 2014;16(2):111-17. doi: 10.1111/ dom.12128. [Epub 2013 Jun 3].
  20. Chon S., Gautier J-F An Update on the effect of incretin-based therapies on ß-cell function and mass. Diab. Metab. J. 2016;40:99-114.
  21. Wu D., Li L., Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a metaanalysis Diab. Obes. Metab. 2014;16(1):30-7. doi: 10.1111/dom.12174. Epub 2013 Jul 16.
  22. DeFronzo R.A., Hissa M.N., Garber A.J., et al.; Saxagliptin 014 Study Group. The Efficacy and safety of alogliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diab. Care. 2009;32(9):1649-55.
  23. Stahn A., Pistrosch F., Ganz X., et al. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. Diab. Care. 2014;37: 516-20.
  24. Del Prato S., et al. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diab. Obes. Metab. 2014;16(12):1239-46.
  25. Khaled A.A., Sekaran M., Ikram S.I. Type 2 diabetes and vascular complications: A pathophysiologic view. Biomed. Res. 2010;21(2):147-55.
  26. Leon B.M., Maddox T.M. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J. Diab. 2015;6(13):1246-58.
  27. Zoungas S., Patel A. Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Ann. N. Y Acad. Sci. 2010;1212(1):29-40.
  28. Low Wang C.C., Hess C.N., Goldfine A.B. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation. 2016;133:2459-502. Doi:10.1161/ CiRCULATiONAHA.116.022194.
  29. White W.B., Cannon C.P., Heller S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 2013;369:1327-35.
  30. Khan M., Deaton C., Rutter M., etal. Incretinsasanovel therapeutic strategy in patients with diabetes and heart failure. Heart Fail. Rev. 2013;18:141-48.
  31. Chrysant S.G., Chrysant G.S. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am. J. Cardiol. 2012;109(11):1681-85.
  32. Lund A. On the role of the gut in diabetic hyperglucagonaemia. Dan. Med. J. 2017;64(4):pii:B5340.
  33. Pratley R.E., McCall T., Fleck PR., et al. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J. Am. Geriatr. Soc. 2009;57(11):2011-19.
  34. Rosenstock J., Wilson C., Fleck P Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diab. Obes. Metab. 2013;15(10):906-14. doi: 10.1111/dom.12102.
  35. Bron M., Wilson C., Fleck P A post hoc analysis of HbA1c, hypoglycemia, and weight change outcomes with alogliptin vs glipizide in older patients with type 2 diabetes. Diab. Ther. 2014;5:521-34.
  36. Moritoh Y., Takeuchi K., Asakawa T, et al. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol. 2008;588(2-3):325-32.
  37. Kawashima S., Matsuoka T.A., Kaneto H., et al. Effect of alogliptin, pioglitazone and glargine on pancreatic beta-cells in diabetic db/db mice. Biochem Biophys Res Commun. 2011;404(1):534-40.
  38. Zhang X., Wang Z., Huang Y., Wang J. Effects of chronic administration of alogliptin on the development of diabetes and beta-cell function in high fat diet/streptozotocin diabetic mice. Diabetes Obes Metab. 2011;13(4):337-47.
  39. Yin H., Park S.Y., Wang X.J., et al. Enhancing pancreatic beta-cell regeneration in vivo with pioglitazone and alogliptin. PLoS One. 2013;8(6):e65777.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2018
##common.cookie##